Both Advil and Opiates are EQUALLY AS EFFECTIVE .. in getting – FAKE NEWS- media coverage

Does That JAMA Study Really Show That Advil Is Just As Effective As Opioids?

Since responses to pain treatment vary widely, it is hazardous to draw broad conclusions from a single study.

https://reason.com/blog/2018/03/09/does-that-jama-study-really-show-that-ad

According to Vox, a JAMA study published this week “finally” provides “proof” that “opioids are no better than other medications for some chronic pain.” The results of the study are “devastating,” Vox says. To whom or what is not exactly clear, but the author of the article, Julia Belluz, seems to see the study as conclusive evidence against the notion that “opioids help patients with chronic pain in the long run” or that “they are worth all that risk” of “addiction and death.” Similarly, NBC News declares that the “jury’s in,” and its verdict is that “opioids are not better than other medicines for chronic pain.” Mother Jones likewise says “a new study shows that opioids are no better than other meds for chronic pain,” while Newser agrees that Tylenol and Advil “work just as well as opioids.”

The JAMA study—the work of a team led by internist Erin Krebs, a researcher with the Minneapolis Veterans Affairs Health Care System—did not actually demonstrate any of that. But it did highlight journalists’ eagerness to believe that no one really needs narcotics for pain relief, which reflects the widespread desire for a simple solution to the “opioid epidemic.”

If opioids have no advantage over other analgesics, why prescribe them at all? Why risk “addiction and death” when over-the-counter pain relievers are just as effective? Even if we ignore the fact that the risks for pain patients are actually pretty small (and the fact that opioid-related deaths primarily involve illegally produced drugs), this study does not show what the headlines claim.

Krebs and her colleagues recruited 240 patients with moderate to severe chronic back pain or hip or knee osteoarthritis from V.A. primary care clinics and randomly assigned them to opioid or nonopioid treatment. The opioid group initially received immediate-release morphine, oxycodone, or hydrocodone plus acetaminophen. If those medications proved inadequate, subjects were treated with sustained-action morphine or oxycodone, followed by fentanyl patches if necessary. The nonopioid group initially received acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, followed if necessary by various other medications, including nortriptyline, amitriptyline, gabapentin, topical analgesics, pregabalin, duloxetine, and tramadol.

The main outcome measures were pain-related function (measured by a questionnaire, with higher scores indicating a bigger burden from pain) and pain intensity (also self-reported, on a scale of 0 to 10). After 12 months, both groups were significantly better off by those two measures. The mean pain-related function score fell from 5.4 to 3.4 in the opioid group and from 5.5 to 3.3 in the nonopioid group. Mean pain intensity fell from 5.4 to 4 in the opioid group and from 5.4 to 3.5 in the nonopioid group. The difference between the two groups was statistically significant only for pain intensity, and the researchers note that “the clinical importance of this finding is unclear,” since “the magnitude was small.”

In short, both groups fared about the same. “Treatment with opioids was not superior to treatment with nonopioid medications for improving pain-related function over 12 months,” Krebs et al. conclude. “Results do not support initiation of opioid therapy for moderate to severe chronic back pain or hip or knee osteoarthritis pain.”

People in pain vary widely in how they respond to medication, so the fact that opioids did not have an advantage, on average, for this particular sample with these particular types of pain does not mean they are not a better choice for some patients. The study sample was 87 percent male, and it was drawn from V.A. clinics, which may not be representative of the general patient population. The conditions were limited to chronic back pain and chronic hip or knee pain caused by osteoarthritis, so the study does not speak to opioid treatment for other kinds of pain. The initial pain intensities were middling, so the study may not reflect the experiences of patients with more severe pain.

Notably, the researchers excluded patients who were on long-term opioid therapy, which means they ignored people who had already found they did not get adequate relief from other treatments. It seems reasonable to assume that people who are currently using opioids to treat chronic pain are doing so because they think these drugs work better for them than Advil or Tylenol, and they may even be right to think that. If you exclude those patients from a study of pain treatment, you are excluding precisely the people who are most likely to get more relief from opioids.

The bottom line is that patients should be able to get the medications that work best for them. Many people with severe chronic pain report going through a long list of alternative treatments before finding that opioids were the only thing that kept the agony at bay and gave them a decent quality of life. A study like this one is utterly irrelevant to people in that situation, and to suggest otherwise is illogical as well as cruel.

Addendum: Krebs notes that the study included patients who had tried opioids or who were using them intermittently, provided they were taking fewer than 60 short-acting tablets per month. “To be eligible for the study, we required patients to have moderate-severe pain despite analgesic use,” she writes in an email. “All patients in the study had tried and failed other analgesics….We excluded people with more frequent opioid use because they would need tapering/discontinuation of opioids if randomized to the nonopioid arm. Long-term opioid use causes physiological dependence (a phenomenon distinct from addiction), which generates additional clinical complexity.”

I want to hear from you

Hi Steve –

Did you know that the ACLU has sued every president since our founding nearly 100 years ago? Every single president – from both of our two major political parties. No matter who’s in charge, we know our job is to defend the Constitution.

The ACLU is a nonpartisan organization, and we believe civil rights and liberties shouldn’t be partisan issues. These fundamental freedoms guaranteed by our Constitution transcend party lines.

That’s why it’s crucial that all of us stay active this year. We have to do everything we can to stop Donald Trump’s extraordinary assault on the Constitution and his reckless efforts to trample on people’s rights. That means using every bit of influence we can muster to influence decisions that affect the future of civil liberties.

Wherever you fall on the political spectrum, you have an important role to play to uphold our American values. Please take this short survey so we can identify activism opportunities for you to make the biggest impact.

There have always been conservatives and progressives among the ranks of the ACLU. Democrats, Republicans, Libertarians, Socialists – the banner of civil liberties is big enough to cover all of us.

We’ve been vocal in our opposition to the Trump administration’s policies – as we have been with every previous administration. But things are different now. This administration’s behavior isn’t normal by any definition.

That’s why we plan to engage in nonpartisan issue advocacy around the 2018 elections. We want all candidates to respect the rights and liberties of everyone in this country – and we know ACLU supporters will demand no less. We’ll work with supporters like you to ensure that all voters have the information they need to evaluate candidates’ positions on the key civil rights and liberties issues of our time.

We want to make sure we’re giving you the most relevant and meaningful opportunities to get involved. Will you take this quick survey to tell us about yourself?

If you’ve chipped in to an elected representative before, our advocates might enlist you to contact them on a key vote protecting our fundamental freedoms. Or if members of your political party are putting a core value of yours on the line, we might ask you to step up and make your voice heard.

The more you share in this short survey, the easier it will be for our advocates and organizers to match you up with opportunities to defend and protect civil liberties. We won’t ask more of you than you can manage – but we will ask you to step up in meaningful ways. That’s part of what it means to be an ACLU supporter in such an unprecedented time.

Thanks for fighting for our values,

Anthony D. Romero
ACLU Executive Director

 

institutions are ignoring the law in order to get the execution drugs they need to carry out the death penalty

ACLU: Nebraska Illegally Obtaining and Storing Execution Drugs

https://www.newsmax.com/newsfront/aclu-nebraska-execution-drugs-fentanyl/2018/03/12/id/848168/

The state of Nebraska has been breaking federal law to obtain and store an experimental drug cocktail used in lethal injections, the American Civil Liberties Union alleges in a complaint filed Monday.

The ACLU of Nebraska, along with the DEA, has filed a complaint which claims that Nebraska unlawfully obtained fentanyl, a Schedule II controlled substance, in order to execute prisoners Jose Sandoval and Carey Moore, arguing that the DEA ought to seize the drugs before they are used.

 “As the complaint shows, a person or entity, including government agencies, needs a DEA registration to import a controlled substance,” wrote Danielle Conrad, ACLU of Nebraska executive director, on Monday. “Federal law also requires those that handle a controlled substance to have a DEA registration particular to their authorized usage. These laws apply to the Nebraska Department of Corrections and to the Nebraska State Penitentiary (NSP), where the state carries out executions. But both institutions are ignoring the law in order to get the execution drugs they need to carry out the death penalty.”
 The ACLU notes that the NSP applied to register as a DEA importer in multiple years with a false pharmacy license number, one registered to a pharmacy that the Department of Corrections operates four miles away despite the license being specific to the pharmacy’s address and the people listed in the application.

“Put simply, the state broke the federal law by applying for an import registration for the prison based on the false claim that the prison possessed a state pharmacy license it did not,” Conrad continued. “That licensed was assigned to the state pharmacy, and Nebraska law forbids it from being assigned, borrowed, or used by some other person or entity. In fact, in 2011, the pharmacy itself used this very same license number to apply legally for its own DEA import registration. When the NSP did the same, it was illegal.”

Jose Sandoval  After he was sent to death row, Sandoval pleaded guilty to two additional murders in the months leading up to the bank slayings  http://www.omaha.com/townnews/criminal_law/jose-sandoval-argues-he-was-illegally-sentenced-to-death-when/article_61c613a0-db7d-11e7-b3c9-ff2e1dad2bfd.html

Carey Moore Moore shot and killed Omaha cab drivers Reuel Van Ness and Maynard Helgeland in the summer of 1979.  http://www.omaha.com/news/nebraska/nebraska-notifies-death-row-inmate-carey-dean-moore-of-drugs/article_1e5f1c5c-fd5a-11e7-9b15-773ca0854563.html

The notice provided Friday to Moore said the state intends to use a series of four drugs — in order: diazepam, fentanyl citrate, cisatracurium besylate and potassium chloride — to carry out the execution.

Doesn’t it just give you the “warm fuzzies” to know that the ACLU is defending the rights of murders to not be executed by  FDA APPROVED drugs.

The DEA has plainly stated that the use of a opiate and a benzo can be FATAL… throw in a paralytic agent (stop breathing) and Pot Cl to stop the heart from beating.. should work !    Where are they in defending the rights of chronic pain pts to have access to medically necessary medications ?  I forgot, the 8th Amendment – cruel and unusual punishing – only applies to PRISONERS …

US justice (DOJ) dismissed my inquiry as they are too busy.

.  I am a chronic pain patient who has been on opioids since 2008.  I have degenerative disc disease.  I weakened my spine doing rigorous landscaping on a long trunk, I subsequently damaged it worse during an active sporting event.  I have had three back surgeries to remove disc material and one fusion.  I have permanent awful sciatica from permanent nerve damage & granulation tissue. 

 

I need help.  Back in October, I literally lost my job because my prescription was not delivered on time.  They are trying and being successful at making me wait till day 28 of a 28 day script.  I have always picked up on day 27 and in the past 3 years, and way back it was 5 days day 24.  Laws in federal and new york coincide to 5 days but pharmacy has own illegal policy?  Lost my job in october because of this hold, then when it was my day for them, they couldn’t get my medicine in stock within 48 hours, subsequently ran put within 12 hrs, had pain and pain anxiety resulting in issue at work and termination the following Monday.

  Complained to CVS and US Justice department to a person actually arguing what happened at CVS corporate.  Us justice dismissed my inquiry as they are too busy. 

I am at a loss Steve.  I moved here for that job and loved it.  Am now out over 20,000 dollars since this winter, cant find work in my field, going broke.   There is a bullseye on my back!

 

I used to take 3-30mg OC oxycontins per day with 4 by 10s/325 perks. That was 2010/2011 around surgeries.  Doctor has reduced to 15mg oxycodone IR x4 with muscle relaxants.  I need more but the doc wont move because I am at 90MME.  He will not even give me one dose per day!  There is money involved here and I am getting royally shafted. 

 

Nys law is not clear; says pharmacists can refuse but must pass on to guarantee care.  They cannot interfere or obstruct patients access to their medicine, yet it happened to me last month.  I dropped off, requested Saturday as it was reasonable at 2 days, promised by pharmacist herself.  Saturday came, different pharmacist said 6:45am while in pain and extremely low, “im not filling that, too early, come back tomorrow”. I had literally one tablet left.  My doctor gives 4 oxy ir per day, i was taken off the extended oxycontin because the new formula is junk, messed me up and literally caused holes in small bowel because glue/polymers.   Oxy ir works great with little side effect but i cant get 6 hours.  5 hrs okay most times and i always take it within label rate not more than 1 tablet per 4 hours.  Its a damm struggle to make each month and my doctor has a hard on for CDC recommendations.  Literally his child could be dying, he wont lift his hand an inch.  Totally brainwashed by GOV.   Its about doctor license 1st everyday of the year.

 

I’m sick of this crap, i need a friend and attorney and don’t see an absolute in law code.

AG Session: The Department of Justice under my watch is committed to transparency and the rule of law

I just made the post above a couple of days ago… apparently those within the DOJ didn’t get the memo from AG Session about the DOJ being committed to the “rule of law”. Perhaps AG Session is just using  “committed to transparency and the rule of law”  as just a good sounding “sound bite” and there is really no substance to it for the DOJ. Just more political BULL SHIT ? 🙁

 

AG Session: The Department of Justice under my watch is committed to transparency and the rule of law

DOJ to release Fast and Furious details Holder kept hidden

http://www.wnd.com/2018/03/doj-to-release-fast-and-furious-details-holder-kept-hidden/

Attorney General Jeff Sessions announced Wednesday that documents related to the failed Fast and Furious federal gun-running program that former Attorney General Eric Holder kept hidden are going to be released.

Katie Pavlich at Townhall noted Holder was voted “in civil and criminal contempt of Congress” for his actions.

Obama invoked executive privilege in June 2012 to prevent the release of the documents after the courts had said they could be publicized.

The DOJ said Wednesday the documents will be turned over to the House Oversight Committee.

“The Department of Justice under my watch is committed to transparency and the rule of law.

This settlement agreement is an important step to make sure that the public finally receives all the facts related to Operation Fast and Furious,” Sessions announced.

The release is part of the settlement of a federal case that stemmed from the Obama administration’s refusal to share the information with Congress.

The Fast and Furious plan was to allow highly specialized weapons to be sold so they could be traced to Mexican drug-cartel leaders.

 

But the Obama administration lost track of many of the weapons, and some were used in murders, including the slaying of Border Patrol Agent Brian Terry.

In a Fox News interview, Terry’s brother called on the Trump administration to reopen the investigation into the operation and to release previously withheld documents.

“We need to find out the truth, exactly what happened, how it happened, why it happened. We need Mr. Trump, President Trump, to unseal the documents, reverse executive privilege so that we know what happened, and that we can hold the people accountable that are responsible,” Kent Terry said.

Brian Terry died at the hands of Mexican cartel members in December 2010. They were carrying guns illegally trafficked by ATF to Mexico through the Fast and Furious program.

The operation trafficked “thousands of AK-47s,” as well as .50 caliber rifles.

WND reported two years ago that the failed sting operation was linked to an additional 69 deaths, including a massacre in which 22 died, in addition to the 200 deaths in Mexico alone that were reported in previous years.

I made this post… not because of the context of it..but.. because AG Session keeps talking about “the rule of law” under his watch. There a increasing number of insurance companies, PBM’s, healthcare corporations that are putting things in place that will end up with discriminating against the care that those in the chronic pain community will receive.

How to File an ADA Complaint with the U.S. Department of Justice

If AG Session  is so committed to “the rule of law” then this agency under the Dept of Justice should start taking – and acting on – complaints of discrimination from the chronic pain community SERIOUSLY..  Doesn’t make any difference if it is the DEA, CDC, FDA, CMS, HHS, state legislatures, insurance companies, PBM’s, healthcare corporations if his DOJ is going to enforce all laws equally… then let’s see if he will keep his word. or he is just using this “sound bite” to make  point about a particular issue that he feels warrants to be enforced ?

To date, most of what I have heard is that this part of DOJ … doesn’t have the resources…  Perhaps as more and more chronic painers file their complaints and take those “not enough resources” to the media. Our government can spend 81 billion/yr to fight the war on drugs… but… doesn’t have the resources to protect millions and millions of citizens who are being discriminated against by our own government ?

 

What the JAMA Opioid Study Didn’t Find

www.painnewsnetwork.org/stories/2018/3/10/what-the-krebs-opioid-study-didnt-find

A recent opioid study published in the Journal Of the American Medical Association (JAMA)  evaluated pain management in patients with hip and knee osteoarthritis and low back pain.

The study by VA researcher Erin Krebs, MD, and colleagues found that “treatment with opioids was not superior to treatment with nonopioid medications for improving pain-related function over 12 months.”  

That finding was widely and erroneously reported in the news media as meaning that opioids are ineffective for all types of chronic pain.

bigstock-Chronic-Pain--Medical-Concept-89339426.jpg

But the most fascinating result of the study – the one not being reported — is what wasn’t found. The 108 people in the study who took opioids for a year did not develop signs of opioid misuse, abuse or addiction, and did not develop opioid-induced hyperalgesia – a heightened sensitivity to pain.

And no one died of an overdose.

This is significant because it runs counter to commonly held beliefs in the medical profession about the risks of prescription opioids. Here are a few recent examples:

“Opioids are very addictive and their effectiveness wanes as people habituate to the medication,” Carl Noe, MD, director of a pain clinic at the University of Texas Medical Center wrote in an op/ed in The Texas Tribune.

Don Teater, MD, a family physician in North Carolina, also believes that people on long-term opioid therapy experience dose escalation, which leads to hyperalgesia. “Opioids cause permanent brain changes,” Teater told USA Today.

Krebs herself has made similar comments. “Within a few weeks or months of taking an opioid on a daily basis, your body gets used to that level of opioid, and you need more and more to get the same level of effect,” she told NPR.

But the Krebs study didn’t see any of that happen.

Krebs and colleagues closely monitored the 108 people in the opioid arm of the study, using “multiple approaches to evaluate for potential misuse, including medical record surveillance for evidence of ‘doctor-shopping’ (seeking medication from multiple physicians), diversion, substance use disorder, or death.” They also had participants complete the “Addiction Behavior Checklist” and assessed their alcohol and drug use with surveys and screening tools.

What did Krebs find in the opioid group after 12 months of treatment?

“No deaths, ‘doctor-shopping,’ diversion, or opioid use disorder diagnoses were detected,” she reported. “There were no significant differences in adverse outcomes or potential misuse measures.”

Health-related quality of life and mental health in the opioid group did not significantly differ from the non-opioid group – and their anxiety levels actually improved.  

These are observational findings in the study. They were not a part of what Krebs and colleagues were specifically trying to measure. As the study notes: “This trial did not have sufficient statistical power to estimate rates of death, opioid use disorder, or other serious harms associated with prescribed opioids.”

 ERIN KREBS, MD

ERIN KREBS, MD

But they are valuable observations. They note what didn’t happen in the study. Over 100 people were put on opioid therapy for a year, and none of them showed any signs of dose escalation or opioid-induced hyperalgesia, or any evidence of opioid misuse, abuse or addiction.

Krebs told the Minneapolis Star Tribune that this “could reflect the fact that the study did not enroll patients with addiction histories, and because the VA provided close supervision to all participants during the yearlong study.”

In other words, Krebs and colleagues used an opioid prescribing protocol that achieved an admirable level of patient safety. Their approach is similar to what many pain management practices currently pursue and what the CDC and various state guidelines recommend: Risk assessment before initial prescribing and careful monitoring over time.

The Krebs study provides rare and detailed observations of what happens when people are put on long-term opioid therapy. A lot of what is claimed about dose escalation, opioid-induced hyperalgesia, and misuse or abuse didn’t happen at all.

This outcome demonstrates that long-term opioid therapy can be safe and effective, and may be useful in treating other chronic conditions, from intractable neuropathies to painful genetic disorders. That’s worth reporting too, isn’t it?

 

 

 

Roger Chriss.jpg

Roger Chriss lives with Ehlers Danlos syndrome and is a proud member of the Ehlers-Danlos Society. Roger is a technical consultant in Washington state, where he specializes in mathematics and research.

The information in this column should not be considered as professional medical advice, diagnosis or treatment. It is for informational purposes only and represents the author’s opinions alone. It does not inherently express or reflect the views, opinions and/or positions of Pain News Network.

DON’T PUNISH PAIN RALLY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dear Friends and Family,

I am writing you to invite you to an event in Arizona.  Many of you know that I am an advocate on behalf of the chronic pain community.  This year, on Saturday April 7, one of our advocacy groups is planning a nationwide rally called Don’t Punish Pain.  The false information we are being fed by the media is fueling the rapid rise of overdose deaths from illegal drugs, primarily imported fentanyl (not rx fentanyl) and heroin.

In its misguided and ignorant attempt to counter what it calls the Opioid Epidemic (which it isn’t; it’s an illegal drug crisis), the government is continually stripping away the civil rights of pain patients simply because of the type of medication they need.  The result of this is more death; once a patient has been abandoned by his/her physician and cannot get help, they are left with 3 choices:  to suffer a bedridden life to an early death from pain complications, to turn to street drugs, or to commit suicide.  The attached chart will show you the results.

In spite of these useless, punitive, Draconian measures, overdose deaths are going UP all across the country.  Addicts aren’t being “saved,” but these restrictive policies are torturing pain patients who were compliant and stable in their treatment.  No one is immune; these guidelines and restrictions are affecting ANYONE in pain – and that includes cancer victims, post-operative patients, as well as palliative care and hospice patients.  Our veterans are being hit the hardest.

I am inviting you all to the Don’t Punish Pain rally of your choice. I’m attaching a document that shows which states are participating so far (we have 30), and which states still need a spokesperson.  I am the spokesperson for Arizona, so I am also attaching Arizona’s event flier.  I am also adding a form letter you can use for legislators, doctors and medical personnel, and for the media.  Doctors are another target of this opioid crackdown: they are being raided by the DEA, arrested, and attacked without cause, which are among the biggest reasons they stop prescribing life-saving medication to patients.

I am also inviting you to participate in any way you can.  This is not a march or a fund-raiser; this is a rally to bring awareness to what this crackdown on opioid prescribing is really doing to our country.  Each of us, if not already in chronic pain, is just one motor vehicle accident, one illness, one surgery away from a lifetime of chronic pain.  And while there are other therapies for pain, many are dangerous, most are not covered by insurance, and no one has developed a true replacement for opioid medication.  The rug was jerked out from under us without anything in place to catch us when our doctors’ practices are closed down by the DEA, or our doctors kick us to the curb on trumped-up charges, even to the extent of lying about the results of a urine test.

You can help by:

Spreading the word.  You can do this with letters, phone calls, social media like Facebook and Twitter, and personal emails (like this one).  Print and share the flier appropriate to your state (or states, if you like).  Take the fliers with you wherever you go, and ask permission for them to be posted.

Attending a rally of your choice.  Numbers are important, and we are also in need of able-bodied people for support.  Please note that while the nationwide rallies are being held at 12 noon EST, the Arizona rally will be at 10:00am (I forgot to account for daylight savings time).  We need your presence.

From the attached list of states, if you have friends in unrepresented states, please share this with them for encouragement.  Hopefully, someone in each of these states will be willing to step forward to lead as a spokesperson.

Please pray for me, my family, and my health.  I’m fighting chronic illness as well as chronic pain, and would dearly love your prayers for wisdom, clarity, and physical strength to see this through.  I am very blessed to have Pat at my side, helping me.

Thank you for taking the time to read this rather long letter.  If for any reason you do not want to be on this mailing list, please let me know.  I don’t want to clog your inbox with unwanted emails.

Thank you all,

Lauri

 

 

Nondiscrimination Standards Under ACA Section 1557: Now Is the Time to Act

https://www.ebglaw.com/news/nondiscrimination-standards-under-aca-section-1557-now-is-the-time-to-act/

Health Care and Life Sciences Client Alert September 15, 2016

Epstein Becker Green Health Care and Life Sciences Client AlertHealth insurers and group health plan sponsors must closely review the final rule titled “Nondiscrimination in Health Programs and Activities” (“Final Rule”) implementing Section 1557 of the Affordable Care Act (“ACA”) that was published by the U.S. Department of Health and Human Services (“HHS”) on May 18, 2016.[1] Section 1557 prohibits discrimination on the basis of race, color, national origin, sex, age, or disability in certain health programs and activities. To address issues of discrimination in the health programs and activities of certain “Covered Entities” (defined below), the Final Rule clarifies and codifies existing nondiscrimination requirements and sets forth new standards to implement Section 1557, particularly with respect to the prohibition of discrimination on the basis of sex.

The Final Rule became effective on July 18, 2016; however, for those insurance issuers or group health plans that must alter their plan benefit designs based on the Final Rule, the effective date is the first day of the first plan or policy year on or after January 1, 2017. Regardless of the date and mechanism through which the Final Rule applies to you, now is the time to ensure that you understand the rule’s requirements and implement needed policy or operational changes.

Key Implementation Elements of the Final Rule

Who: A health program or activity, any part of which receives federal financial assistance, and any program or activity administered by an executive agency or an entity established under Title I of the Affordable Care Act

What: An individual may not be excluded from participation in, denied the benefits of, or otherwise subjected to discrimination on the basis of race, color, national origin, sex, age, or disability in, certain health programs and activities

When: Effective July 18, 2016, unless changes to health insurance or group health plan benefit design (including covered benefits, benefits limitations or restrictions, and cost-sharing mechanisms, such as coinsurance, copayments, and deductibles) are required—in which case, provisions will apply on the first day of the first plan year (or policy year in the individual market) beginning on or after January 1, 2017

Definitions

HHS, through such agencies as the Health Resources and Services Administration (“HRSA”), the Substance Abuse and Mental Health Services Administration (“SAMHSA”), the Centers for Disease Control and Prevention (“CDC”), and the Centers for Medicare & Medicaid Services (“CMS”), provides federal financial assistance via various mechanisms to health programs and activities of local governments, state governments, and the private sector.

“Federal financial assistance” includes grants, loans, subsidies, contracts of insurance, and other types of assistance. Such assistance also includes premium tax credits and advance payments of premium tax credits and cost-sharing reductions for health insurance coverage purchased through the Health Insurance Marketplaces.[2]

“Covered Entities” that are subject to the non-discrimination provisions in the Final Rule include:

  • Entities receiving federal financial assistance through their participation in Medicare (excluding Medicare Part B[3]) or Medicaid—for example:
    • short-term, rehabilitation, psychiatric, and long-term hospitals
    • facility-based and freestanding skilled nursing facilities/nursing facilities
    • home health agencies
    • physical therapy/speech pathology programs
    • end-stage renal disease dialysis centers
    • intermediate care facilities for individuals with intellectual disabilities
    • rural health clinics
    • independent practice physical therapy
    • comprehensive outpatient rehabilitation facilities
    • ambulatory surgical centers
    • hospices
    • organ procurement organizations
    • community mental health centers
    • Federally Qualified Health Centers
  • Hospital-based, office-based, or freestanding laboratories that receive federal financial assistance through Medicaid payments for covered laboratory tests
  • Community health centers receiving federal financial assistance through grant awards from HRSA
  • Health-related schools in the United States and other health education entities receiving federal financial assistance through grant awards to support health professional training programs that include oral health, behavioral health, medicine, geriatric, and physician’s assistant programs
  • State Medicaid agencies receiving federal financial assistance from CMS to operate the Medicaid Program, the Children’s Health Insurance Program (“CHIP”), and the Basic Health Program
  • State public health agencies receiving federal financial assistance from CDC, SAMHSA, and other HHS components
  • Health Insurance Marketplaces established under Title I of the ACA (including 17 State-Based Marketplaces and 34 Federally Facilitated Marketplaces)
  • Qualified health plan issuers receiving federal financial assistance through advance payments of premium tax credits and cost-sharing reductions (which include the health insurance issuers in the Federally Facilitated Marketplaces receiving federal financial assistance through advance payments of premium tax credits and cost-sharing reductions and issuers operating in the State-Based Marketplaces)
  • Physicians receiving federal financial assistance through Medicaid payments, “meaningful use” payments,[4] and other sources

The term ‘‘health program or activity’’ means “the provision or administration of health-related services, health-related insurance coverage, or other health-related coverage, and the provision of assistance to individuals in obtaining health-related services or health-related insurance coverage.”[5] For a Covered Entity that is principally engaged in providing or administering health-related services, health-related insurance coverage, or other health-related coverage, all of its operations are considered part of the health program or activity, including the provision of an employee health benefit program or wellness program to its employees.[6] Accordingly, if any part of a health care entity receives federal financial assistance, then all of its programs and activities are subject to the non-discrimination provisions in the Final Rule. However, the Final Rule does not apply to actions against a Covered Entity’s own employees, including actions related to hiring, firing, promotion, or terms and conditions of employment.

Application of the Nondiscrimination Provisions

The core objective of Section 1557 is to prohibit discrimination in “any health program or activity” on the grounds prohibited under Title VI of the Civil Rights Act of 1964[7] (race, color, or national origin), Title IX of the Education Amendments of 1972[8] (sex), the Age Discrimination Act of 1975[9] (age), and Section 504 of the Rehabilitation Act of 1973[10] (disability). The Final Rule is not intended to apply a lesser standard for the protection of individuals from discrimination than the standards and regulations already applied under these laws. Further, nothing in the Final Rule is intended to be interpreted to invalidate or limit the existing rights, remedies, procedures, or legal standards available to individuals aggrieved under other federal civil rights laws or to supersede state or local laws that provide greater or equal protection against discrimination on the basis of race, color, national origin, sex, age, or disability. The HHS Office of Civil Rights (“OCR”), the agency responsible for enforcing Section 1557, concludes that the regulations promulgated in the Final Rule preempt state law only where the exercise of state authority directly conflicts with or prevents the application of the Final Rule.

HHS did not include a blanket religious exemption in the Final Rule; however, the Final Rule includes a provision noting that, insofar as the application of any requirement under the rule would violate applicable federal statutory protections for religious freedom and conscience, such application would not be required.[11] Further, HHS allows for sex-specific health programs or activities, but only where the Covered Entity can demonstrate an exceedingly persuasive justification (i.e., that the sex-specific program is substantially related to the achievement of an important health-related or scientific objective).[12]

HHS establishes numerous requirements for Covered Entities under the Final Rule. For example, a Covered Entity:

  • must take reasonable steps to provide meaningful access to each individual with limited English proficiency;
  • must take appropriate steps to ensure that communications with individuals with disabilities are as effective as communications with others in health programs and activities;
  • if covered by the 2010 Americans with Disabilities Act (“ADA”) Standards for Accessible Design prior to July 18, 2016, must comply with those standards for new construction or alterations by July 18, 2016, and compliance with the Uniform Federal Accessibility Standards will be deemed compliance with the Final Rule only if construction or alteration was commenced before July 18, 2016, and the facility or part of the facility was not covered by standards under the ADA;
  • must ensure that its health programs or activities provided through electronic and information technology are accessible to individuals with disabilities, unless doing so would result in undue financial and administrative burdens or a fundamental alteration in the nature of the health programs or activities;
  • must provide individuals equal access to its health programs or activities without discrimination on the basis of sex and must treat individuals consistent with their gender identity;
  • must not discriminate on the basis of race, color, national origin, sex, age, or disability when providing or administering health-related insurance or other health-related coverage;
  • will be liable for violations of the Final Rule in any employee health benefit program that it provides to its employees and/or their dependents; and
  • must not exclude from participation in, deny the benefits of, or otherwise discriminate against an individual or entity in, its health programs or activities on the basis of the race, color, national origin, sex, age, or disability of an individual with whom the individual or entity is known or believed to have a relationship or association.[13]

Actions That Covered Entities Must Take to Comply with the Final Rule

Each entity applying for federal financial assistance, each issuer seeking certification to participate in a Health Insurance Marketplace, and each state seeking approval to operate a State-Based Marketplace is required to submit an assurance that its health programs and activities will be operated in compliance with Section 1557.[14]

Each Covered Entity that employs 15 or more persons must designate at least one employee to coordinate compliance with the requirements of the Final Rule.[15] A Covered Entity that has already designated a responsible employee pursuant to the regulations implementing Section 504 or Title IX may use that individual to coordinate its efforts to comply with Section 1557.

Further, a Covered Entity that employs 15 or more persons must adopt a grievance procedure that incorporates appropriate due process standards and allows for the prompt and equitable resolution of complaints concerning actions prohibited by Section 1557.[16] HHS clarifies that an individual does not have to exhaust a Covered Entity’s grievance procedure prior to filing a Section 1557 complaint. Additionally, HHS clarifies that a Covered Entity that already has a grievance procedure addressing claims of disability discrimination that meets the standards established under the Section 504 regulation may use that procedure to address disability claims under Section 1557. A Covered Entity may use that procedure to address all other Section 1557 claims, provided that the Covered Entity modifies the procedure to apply to race, color, national origin, sex, and age discrimination claims. HHS provides an example of how to structure a grievance procedure in Appendix C of the Final Rule.[17]

A Covered Entity must take appropriate initial and continuing steps to notify beneficiaries, enrollees, applicants, or members of the public of individuals’ rights under Section 1557 and of Covered Entities’ nondiscrimination obligations with respect to their health programs and activities.[18] Specifically, a Covered Entity’s notice must include the following statements and information:

  • The Covered Entity does not discriminate on the basis of race, color, national origin, sex, age, or disability
  • The Covered Entity provides appropriate auxiliary aids and services, free of charge and in a timely manner, to individuals with disabilities
  • The Covered Entity provides language assistance services, free of charge and in a timely manner, to individuals with limited English proficiency
  • How an individual can access such aids and services referenced above
  • The contact information for the responsible employee coordinating compliance with Section 1557 (when required)
  • The availability of a grievance procedure (when required), and how to file a grievance
  • How an individual can file a discrimination complaint with HHS

This notice must be posted in significant publications and communications, in conspicuous physical locations, and on the Covered Entity’s website by October 16, 2016 (90 days from the effective date of the Final Rule). HHS provides a sample notice and non-discrimination statement in Appendix A of the Final Rule.[19] Covered Entities may use the sample notice or they may develop their own. Covered Entities are encouraged, but not required, to post the notice in one or more of the most prevalent non-English languages frequently encountered in their geographic service areas. Further, Covered Entities may combine the required content of the notice with the content of other required notices, as long as the combined notice clearly informs individuals of their civil rights under Section 1557. However, a Covered Entity’s compliance with the notification requirements in the Final Rule does not constitute compliance with the notice requirements of other federal civil rights laws, such as Title IX and Section 504.

Covered Entities must also post by October 16, 2016, taglines in at least the top 15 languages spoken by individuals with limited English proficiency in the state or states where the Covered Entity operates.[20] HHS provides a sample tagline in Appendix B of the Final Rule.[21] Covered Entities may develop their own taglines, and they may choose to include taglines in more than 15 languages. Further, for significant publications and significant communications that are small-sized, Covered Entities must include the non-discrimination statement (in lieu of the full notice) and taglines in at least the top two languages spoken by individuals with limited English proficiency in the relevant state or states. OCR has posted translated resources in 65 languages, including a notice of nondiscrimination, a statement of nondiscrimination, and taglines, on its website for Covered Entities to use.[22]

A recipient of federal financial assistance or State-Based Marketplace that has been found to have discriminated on any of the bases prohibited by Section 1557 will be required to take remedial action to overcome the effects of that discrimination.[23] Further, a Covered Entity may take voluntary action in the absence of a finding of discrimination to overcome the effects of conditions that result or resulted in limited participation by persons based on race, color, national origin, sex, age, or disability.[24]

Equal Program Access on the Basis of Sex

The Final Rule requires Covered Entities to provide “equal access to its health programs or activities without discrimination on the basis of sex.”[25] The Final Rule uses the same definition for “on the basis of sex” as the proposed rule, which was released by HHS on September 8, 2015 (“Proposed Rule”).[26] Specifically, this term “includes, but is not limited to, discrimination on the basis of pregnancy, false pregnancy, termination of pregnancy, or recovery therefrom, childbirth or related medical conditions, sex stereotyping, and gender identity.”[27]

Sex Stereotyping

OCR continues to rely upon the U.S. Supreme Court’s holding in Price Waterhouse v. Hopkins[28] to support its inclusion of sex stereotyping in the definition of “on the basis of sex.” In the Final Rule, OCR clarified that sex stereotypes can be based on expectations about gender roles.   

Sexual Orientation

Under the Final Rule, OCR will evaluate complaints alleging sex discrimination related to an individual’s sexual orientation to determine whether the complaints can be addressed under Section 1557. In explaining this decision, OCR noted that it received comments both requesting OCR to explicitly state that discrimination on the basis of sex includes discrimination based on sexual orientation and, conversely, asserting that OCR does not have such authority to include sexual orientation because no federal appellate court has interpreted Title IX or Title VII to protect a same-sex relationship.

While acknowledging that no federal appellate court has concluded that federal laws prohibiting sex discrimination include a prohibition on sexual orientation discrimination, OCR noted that some recent court decisions have found that discrimination relating to an individual’s sexual orientation is prohibited because it constitutes discrimination on the basis of sex stereotyping.

As such, OCR concluded that “Section 1557’s prohibition of discrimination on the basis of sex includes, at a minimum, sex discrimination related to an individual’s sexual orientation where the evidence establishes that the discrimination is based on gender stereotypes.”[29] However, OCR did not say that discrimination on the basis of an individual’s sexual orientation alone is a form of discrimination under Section 1557. Covered Entities should pay close attention for legal developments as this area of unsettled law is ripe for litigation.

Gender Identity

Like the Proposed Rule, the Final Rule also requires Covered Entities to “treat individuals consistent with their gender identity.”[30] OCR defines “gender identity” to mean an individual’s internal sense of gender, which may be different than the sex assigned at birth. In response to comments about potential ambiguity regarding non-binary gender identities, OCR revised the Proposed Rule’s definition of “gender identity” to include the clause “which may be male, female, neither, or a combination of male and female.”

The Final Rule also clarifies that the term “gender identity” encompasses “gender expression” and “transgender status.” OCR noted that this is consistent with the position taken by some courts and federal agencies; therefore, these types of discrimination are prohibited under the Final Rule.

Gender Discrimination in Health-Related Insurance and Other Health-Related Coverage

The Final Rule adopts Section 92.207 of the Proposed Rule—which prohibits a Covered Entity from discrimination on the basis of race, color, national origin, sex, age, or disability—without substantive modification. This section also lists specific prohibited practices, including implementing a categorical coverage exclusion or limitation for all health services related to gender transition and denying or limiting coverage for a transgender individuals for any health services that are ordinarily available to individuals of one sex because the person’s sex assigned at birth is different from the one for which such health services are ordinarily available.

OCR refused to provide examples of discriminatory benefit designs. Instead, OCR will analyze “whether a design feature is discriminatory on a case-by-case basis” using the “facts and circumstances of a given scenario.”[31] OCR did acknowledge that Covered Entities have discretion in developing benefit designs and that the Final Rule “does not prevent covered entities from utilizing reasonable medical management techniques; nor does it require covered entities to cover any particular procedure or treatment.”[32] Specifically, OCR changed Section 92.101 to provide that sex-specific health programs or activities are allowable only where the Covered Entity can demonstrate an “exceedingly persuasive justification” that the sex-specific program is “substantially related to the achievement of an important health-related or scientific objective.”[33]

Some commenters expressed concerns that Covered Entities would not be able to revise their health insurance coverages and other offerings by July 18, 2016. OCR refused to delay the implementation of the Final Rule, but to the extent the rule requires changes to health insurance benefit design, OCR did delay implementation until the first day of the first plan year beginning on or after January 1, 2017.

Individuals with Limited English Proficiency and Auxiliary Aids and Services

The Final Rule requires Covered Entities to provide meaningful access to individuals with limited English proficiency.[34] In evaluating compliance with this requirement, the Final Rule requires the Director of the OCR to “evaluate, and give substantial weight to, the nature and importance of the health program or activity and the particular communication at issue to the individual with limited English proficiency.” The Final Rule further requires that the Director “take into account all other relevant factors, including whether the entity has developed and implemented an effective language access plan, appropriate to its particular circumstances.” The specific list of illustrative factors for the Director to consider that was set out in the Proposed Rule is no longer included in the Final Rule.

Covered Entities may need to provide oral language assistance, written translation of documents and websites, and taglines. Language assistance services required must be provided free of charge to individuals with limited English proficiency. These services must also be accurate and timely and protect the individual’s privacy and independence. OCR noted that the definition of “timely” would depend on the circumstances of each situation. Further, OCR would consider the costs of language assistance services and the resources available to the Covered Entity—including the Covered Entity’s ability to leverage resources among its partners—in evaluating whether the requirements of the Final Rule are met.

Even though the Final Rule does not list specific, mandatory methods for providing language assistance, it does contain some important prohibitions. A Covered Entity cannot require an individual to provide his or her own interpreter. The Final Rule also prohibits a Covered Entity from relying on a family member or a minor child to provide translation services, except in an emergency, unless the individual requests that the adult interpret and such assistance is appropriate under the circumstances. Additionally, a Covered Entity cannot require an individual to accept language assistance services. The Final Rule also provides technical requirements for the use of remote video interpretation services.

The Final Rule requires that individuals with disabilities be provided with auxiliary aids and services, including alternative written formats, such as Braille, and sign-language interpreters.

While Section 92.8 of the Final Rule contains an extensive notice required for Covered Entities, OCR modified that section to now only require Covered Entities to post a shorter nondiscrimination statement, along with a limited number of taglines, in significant communications that are small-sized. OCR is translating a sample nondiscrimination statement that Covered Entities can use.

Enforcement

The Final Rule states that OCR will apply existing enforcement mechanisms available under Title VI, Title IX, Section 504, and the Age Discrimination Act of 1975 for purposes of Section 1557 enforcement. Further, compensatory damages for violations of Section 1557 will be available in appropriate administrative and judicial actions brought under the Final Rule.

For recipients of federal financial assistance and State-Based Marketplaces, if such an entity fails to provide OCR with requested information in a timely, complete, and accurate manner, OCR may find noncompliance with Section 1557 and initiate appropriate enforcement procedures, including beginning the process for fund suspension or termination and taking other action authorized by law. Further, an individual or entity may bring a civil action to challenge a violation of Section 1557 in a U.S. district court in which the recipient or State-Based Marketplace is found or transacts business.

For health programs or activities administered by HHS, including the Federally Facilitated Marketplaces, the procedural provisions applicable to Section 504 apply to complaints and compliance reviews concerning discrimination on the basis of race, color, national origin, sex, age, or disability for such health programs and activities. The Final Rule also allows OCR to obtain all of the relevant information needed to investigate a complaint or determine compliance in a particular health program or activity administered by HHS. Further, HHS is prohibited from retaliating against any individual for the purpose of interfering with any right or privilege under Section 1557.[35]

Considerations for Implementation of the Final Rule

The intent of the Final Rule is to provide consumers and Covered Entities with a set of standards that will help them understand and comply with the requirements of Section 1557. The determination of whether a certain practice is discriminatory typically requires a nuanced analysis that is fact-dependent; therefore, it is not possible to identify all issues and circumstances that may raise compliance concerns. HHS advises that Covered Entities should keep in mind the purposes of the ACA and Section 1557—to expand access to care and coverage and eliminate barriers to access—when interpreting requirements of the Final Rule.

In general, Covered Entities have been subject to preexisting requirements in federal civil rights laws related to the prohibition of race, color, national origin, age, or disability discrimination for years. The prohibition of sex discrimination, however, is new for many Covered Entities and will likely require changes in action and behavior to comply with this new prohibition. Further, Covered Entities should consider whether they will provide training to the appropriate staff and incorporate the requirements of the Final Rule into their existing non-discrimination policies and procedures.

*  *  *

This Client Alert was authored by Helaine I. Fingold, Lesley R. Yeung, and Jonathan K. Hoerner. For additional information about the issues discussed in this Client Alert, please contact one of the authors or the Epstein Becker Green attorney who regularly handles your legal matters.


ENDNOTES

 

[1] 81 Fed. Reg. 31,375 (May 18, 2016), available at https://www.gpo.gov/fdsys/pkg/FR-2016-05-18/pdf/2016-11458.pdf.

[2] An issuer participating in a Health Insurance Marketplace is receiving federal financial assistance, but a health care provider that contracts with such an issuer does not become a recipient of federal financial assistance by virtue of the contract. Similarly, physicians who contract to provide health services to hospitals or clinics that receive federal financial assistance do not become a recipient of federal financial assistance by virtue of the contract. However, many health care providers are expected to be subject to Section 1557 due to federal financial assistance that they receive in their own right.

[3] HHS does not consider Medicare Part B payments to physicians to be federal financial assistance.

[4] The Medicare Access and CHIP Reauthorization Act sunsets the “meaningful use” payment adjustments for Medicare physicians after 2018.

[5] 45 C.F.R. § 92.4 (effective July 18, 2016).

[6] See 45 C.F.R. § 92.208 (effective July 18, 2016).

[7] 42 U.S.C. 2000d et seq.

[8] 20 U.S.C. 1681 et seq.

[9] 42 U.S.C. 6101 et seq.

[10] 29 U.S.C. 794.

[11] 45 C.F.R. § 92.2 (effective July 18, 2016).

[12] 45 C.F.R. § 92.101(b)(iv) (effective July 18, 2016).

[13] See 45 C.F.R. §§ 92.201-209 (effective July 18, 2016).

[14] 45 C.F.R. § 92.5 (effective July 18, 2016).

[15] 45 C.F.R. § 92.7(a) (effective July 18, 2016).

[16] 45 C.F.R. § 92.7(b) (effective July 18, 2016).

[17] 81 Fed. Reg. at 31,473.

[18] 45 C.F.R. § 92.8(a) (effective July 18, 2016).

[19] 81 Fed. Reg. at 31,472.

[20] 45 C.F.R. § 92.8(d) (effective July 18, 2016).

[21] 81 Fed. Reg. at 31,473.

[22] OCR, Translated Resources for Covered Entities, available at http://www.hhs.gov/civil-rights/for-individuals/section-1557/translated-resources/index.html.

[23] 45 C.F.R. § 92.6(a) (effective July 18, 2016).

[24] 45 C.F.R. § 92.6(b) (effective July 18, 2016).

[25] 45 C.F.R. § 92.206 (effective July 18, 2016).

[26] See Epstein Becker Green Client Alert “HHS Releases Far-Reaching Proposed Rule to Prohibit Discrimination by ‘Covered Entities’ Pursuant to Section 1557 of the Affordable Care Act” (Oct. 14, 2015), available at https://www.ebglaw.com/news/hhs-releases-far-reaching-proposed-rule-to-prohibit-discrimination-by-%E2%80%9Ccovered-entities%E2%80%9D-pursuant-to-section-1557-of-the-affordable-care-act/.

[27] 45 C.F.R. § 92.40 (effective July 18, 2016).

[28] 490 U.S. 228 (1989).

[29] 81 Fed. Reg. at 31,390.

[30] 45 C.F.R. § 92.206 (effective July 18, 2016).

[31] 81 Fed. Reg. at 31,434.

[32] Id.

[33] 81 Fed. Reg. at 31,470.

[34] 45 C.F.R. § 92.201 (effective July 18, 2016).

[35] See 45 C.F.R. §§ 92.301-303 (effective July 18, 2016).

Sessions Admits Feds Can’t Effectively Police Marijuana In States

Sessions Admits Feds Can’t Effectively Police Marijuana In States

www.marijuanamoment.net/sessions-admits-feds-cant-effectively-police-marijuana-in-states/

U.S. Attorney General Jeff Sessions acknowledged on Saturday that the Department of Justice does not have enough resources to enforce prohibition against everyone who violates federal marijuana laws.

“We’re not going to be able, even if we desired, to take over state enforcement of routine cases that might occur,” he said, referring to the growing number of states that have legalized cannabis. “Federal agents are highly paid, highly trained, and they work on cases involving cartels, international organizations, major distribution networks, large amounts of cash. And they deal with criminal organizations, RICO-type cases. And we’re not out there prosecuting those cases every day.”

Nonetheless, the attorney general made clear he believes that DEA agents should be able to enforce federal marijuana laws against anyone who violates them, regardless of state law.

“The law of the United States of America, in case you haven’t heard, applies in every state in the United States,” he said. “And I am not going to tell Colorado or California or someone else that possession of marijuana is legal under United States law.”

Sessions also took a swipe at the medical use of cannabis that is now legal in more than half the states.

“I don’t think it’s healthy, either,” he said. “If I were sick I wouldn’t suggest you take marijuana to cure yourself. I’m not sure it’s proven to be particularly helpful.”

In January, Sessions rescinded an Obama-era memo that generally allowed states to enact their own laws on marijuana without federal interference.

Sessions Rescinds Memo On State Marijuana Laws

“I believe it’s a rule of law question,” Sessions said on Saturday, arguing that the interpretation of the now-defunct Obama policy was “incorrect legally.”

Sessions’s new remarks, which he made in response to an audience question at a Federalist Society event at Georgetown University Law Center, were first reported by the Associated Press.

Going forward, the attorney general said, the feds would be focused not on “small marijuana cases,” but instead on “criminal enterprise” that is “being done on federal lands and parklands and doing destruction to our park system.”

Such activity was designated as that which could trigger enforcement actions under the earlier Obama guidance as well.

The big unanswered question remains to what extend federal law enforcement and prosecutors in Sessions’s department will seek to go after state-licensed marijuana growers, processors and sellers that operate in accordance with local policies.

Trump officials study death penalty for drug dealers in opioid epidemic

www.bangordailynews.com/2018/03/10/news/nation/trump-officials-study-death-penalty-for-drug-dealers-in-opioid-epidemic/

WASHINGTON – The Trump administration is studying new policy that could allow prosecutors to seek the death penalty for drug dealers, according to people with knowledge of the discussions, a sign that the White House wants to make a strong statement in addressing the opioid crisis.

President Donald Trump last week suggested executing drug dealers as a way to make a dent in opioid addiction. Opioids killed nearly 64,000 people in 2016, and the crisis is straining local health and emergency services.

People familiar with the discussions said that the president’s Domestic Policy Council and the Department of Justice are studying potential policy changes and that a final announcement could come within weeks. The White House has said one approach it might take is to make trafficking large quantities of fentanyl – a powerful synthetic opioid – a capital crime because even small amounts of the drug can be fatal. White House officials also are studying tougher noncapital penalties for large-scale dealers.

Trump said last week that the administration would soon roll out unspecified “strong” policies on opioids. White House officials said Trump has privately expressed interest in Singapore’s policy of executing drug dealers.

“Some countries have a very tough penalty, the ultimate penalty, and they have much less of a drug problem than we do,” Trump said during an appearance at a White House summit on opioids last week.

Trump also has endorsed Philippine President Rodrigo Duterte’s approach to the issue; Duterte’s “drug war” has led to the deaths of thousands of people by extrajudicial police killings. Last year, Trump praised Duterte in a phone call for doing an “unbelievable job on the drug problem,” according to the New York Times.

Kellyanne Conway, counselor to the president, is leading much of the work on opioids for the White House. Singaporean representatives have briefed senior White House officials on their country’s drug policies, which include treatment and education, but also the death penalty, and they provided a PowerPoint presentation on that country’s laws.

Singapore’s model is more in line with the administration’s goals for drug policy than some other countries, a senior administration official said.

“That is seen as the holistic approach that approximates what this White House is trying to do,” a senior administration official said.

The Department of Justice declined to comment on the policy discussion. A White House spokesman did not respond to a request for comment Friday.

Federal law currently allows for the death penalty to be applied in four types of drug-related cases, according to the Death Penalty Information Center: murder committed during a drug-related drive-by shooting, murder committed with the use of a firearm during a drug trafficking crime, murder related to drug trafficking and the death of a law enforcement officer that relates to drugs.

Peter Meyers, a professor at the George Washington University School of Law, said he doesn’t agree with the idea of adding more capital crimes for drug dealers, but he said it could be a legal approach: “It very likely would be constitutional if they want to do it.”

The administration’s directives come as prosecutors nationwide are cracking down on higher-level drug dealers and law enforcement officials are looking at increased penalties for fentanyl trafficking and dealing. But at the same time, public health officials – including those in the Trump administration – and many in law enforcement are emphasizing treatment rather than punitive measures for low-level users and those addicted to drugs.

Attorney General Jeff Sessions has directed federal prosecutors to pursue the most severe penalties for drug offenses. The Department of Justice said last year it will aggressively prosecute traffickers of any fentanyl-related substance.

Some argue executing drug dealers could have a raft of unintended consequences, such as deterring people from calling police when they know someone is overdosing.

 While news of capital charges against a drug dealer would spread quickly and possibly be a deterrent, said Daniel Ciccarone, a professor of family and community medicine at the University of California at San Francisco, it could also drive drug users underground.

“It will keep people from any positive interface with police, any positive interface with public health, any interface with doctors,” he said, noting that it could lead to fewer people receiving treatment for their addictions. “People will become afraid and hide. They won’t trust the police, and they won’t trust the doctor either.”

Ciccarone said there is also concern that the laws could ensnare low-level drug dealers, many of whom do not know that their products contain lethal amounts of opioids and some of whom are battling addiction.

“We’re not talking El Chapo-level people,” he said, referring to Joaquín “El Chapo” Guzmán, the former leader of the Sinaloa cartel who was extradited to the United States last year. U.S. officials had to assure their Mexican counterparts that Guzmán would not face the death penalty as part of extradition negotiations.

“The closer you get to the ground, the closer you get to people who are easy to capture and the more unknown the fentanyl issue is,” Ciccarone said. “I don’t believe that expanding the drug penalty further for other trafficking offenses is going to solve the opioid epidemic,” she said.

Regina LaBelle, deputy chief of staff at the Office of National Drug Control Policy in the Obama administration, said that current laws that allow for drug dealers to be charged with a capital offense haven’t had a deterrent effect.

If this comes to be law/policy… could the DEA apply this to prescribers that the DEA have determined to be running “pill mills” and any prescriber that had a pt died from a drug overdose… be subject to a death penalty ?  What would that do to the chronic pain community and/or all those people dealing with subjective disease and have a valid medical necessity for a controlled substance and being able to get their necessary medication ?